Informações do membro
Dr Marta Morales Ballús
Espanha
A Nossa Equipa
Dr Jaume Català Mora
Espanha
Dr Elisa Carreras
Espanha
Dr Itziar Alonso
Espanha
Dr Isabel Ayet
Espanha
Dr Ester Casas
Espanha
Optometrist Ana Díaz
Espanha
Dr Jesús Díaz
Espanha
Optometrist Enric Puigventos
Espanha
Optometrist Carles Fresno
Espanha
Dr Carmen García Vicuña
Espanha
Dr Hugo Gonzalez
Espanha
Optometrist Enrique Jimenez
Espanha
Dr Ana Llorca
Espanha
Dr Antonio Federico Martinez Monstseny
Espanha
Dr Joan Prat
Espanha
Dr Gemma Romeu
Espanha
Dr Alicia Serra
Espanha
Optometrist Simone Suh
Espanha
Dr Mariona Vidal
Espanha
Optometrist Begoña Yeste
Espanha
Dr Núria Planas
Espanha
Centro de saúde
Contacto
Hospital Sant Joan de Déu, Spain
Ensaios clínicos
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation